10-Q: KORU Medical Reports Strong Revenue Growth, Narrows Loss

KORU Medical Systems announced a significant increase in net revenues and a substantial reduction in net loss for the second quarter and first half of 2025, driven by core business expansion and pharma services.

Summary

• Net revenues for the three months ended June 30, 2025, increased by 20.9% to $10.2 million, up from $8.4 million in the prior year period.
• Net revenues for the six months ended June 30, 2025, grew by 19.3% to $19.8 million, compared to $16.6 million in the same period last year.
• Domestic core revenues rose by 15.3% in Q2 2025 to $7.1 million and 15.8% in H1 2025 to $14.0 million, driven by higher consumable volumes, new patient starts, and market share gains.
• International core revenues surged by 33.9% in Q2 2025 to $2.2 million and 34.8% in H1 2025 to $4.6 million, attributed to prefill patient conversions, new patient starts, and expansion into new geographic markets.
• Pharma services and clinical trials net revenues increased by 42.1% in Q2 2025 to $0.9 million and 8.8% in H1 2025 to $1.2 million, primarily due to higher product sales for clinical trials.
• Gross profit for Q2 2025 was $6.5 million, an 18.2% increase, while gross margin slightly decreased to 63.5% from 65.0% in the prior year, mainly due to a one-time inventory valuation adjustment in the prior year and current year tariff charges.
• Net loss for Q2 2025 significantly decreased by 79.1% to $(0.2) million from $(1.0) million in the prior year period.
• Net loss for H1 2025 improved by 53.1% to $(1.4) million from $(2.9) million in the prior year period.
• Cash and cash equivalents stood at $8.1 million as of June 30, 2025, a decrease from $9.6 million at December 31, 2024.
• Net cash used in operating activities increased to $(0.7) million for H1 2025 from $(0.3) million for H1 2024.
• Adam Kalbermatten was appointed Chief Commercial Officer, effective July 28, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth and a significant reduction in net loss, indicating positive operational momentum. While cash usage increased and gross margin slightly declined, these are largely offset by the overall positive financial trajectory and strategic management changes.

Positives

• Net revenues increased significantly by 20.9% in Q2 2025 and 19.3% in H1 2025, demonstrating strong top-line growth.
• Net loss decreased substantially by 79.1% in Q2 2025 and 53.1% in H1 2025, indicating improved operational efficiency and a positive trend towards profitability.
• Domestic core business grew by 15.3% in Q2 2025 and 15.8% in H1 2025, driven by new patient starts and market share gains in a strong underlying SCIg market.
• International core business showed robust growth of 33.9% in Q2 2025 and 34.8% in H1 2025, reflecting successful patient conversions and market expansion.
• Pharma services and clinical trials segment experienced strong growth of 42.1% in Q2 2025, highlighting increasing engagement with biopharmaceutical companies.
• The loan and security agreement was amended to extend the maturity of the revolving credit facility to December 31, 2026, and the interest-only portion of the term loan facility to October 1, 2026, providing enhanced financial flexibility.
• Management expects current cash on hand and cash flows from operations to be sufficient to meet requirements for at least the next twelve months.
• The appointment of Adam Kalbermatten as Chief Commercial Officer is a strategic move to bolster commercial efforts and drive future sales.

Negatives

• Cash and cash equivalents decreased by $1.53 million from $9.58 million at December 31, 2024, to $8.05 million at June 30, 2025.
• Gross margin declined to 63.5% in Q2 2025 from 65.0% in Q2 2024, and to 63.1% in H1 2025 from 63.6% in H1 2024, primarily due to a prior year favorable inventory valuation adjustment and current year tariff-related charges.
• Net cash used in operating activities increased to $(0.7) million for H1 2025 from $(0.3) million for H1 2024, indicating higher cash burn from operations.
• Net cash used in investing activities increased to $(0.5) million for H1 2025 from $(0.3) million for H1 2024, reflecting increased capital expenditures.
• Incurred $0.1 million in tariff-related charges during Q2 2025, with an expected annualized gross margin impact of less than 100 basis points.

Risks

• Uncertainties associated with inflation.
• Impact of tariffs and other geopolitical conflicts.
• Fluctuations in customer ordering patterns.
• Availability and costs of raw materials and labor, and the ability to recover such costs.
• Future operating results may vary.
• Growth of new patient starts and the immunoglobulin (Ig) market.
• Compliance with Food and Drug Administration (FDA) and foreign authority regulations and the outcome of regulatory audits.
• Introduction of competitive products.
• Acceptance of and demand for new and existing products.
• Ability to penetrate new markets.
• Success in enforcing and obtaining patents.
• Reimbursement related risks.
• Government regulation of the home health care industry.
• Success of research and development efforts.
• Expanding the market of the FREEDOM™ System.
• Demand in the subcutaneous immunoglobulin (SCIg) market.
• Availability of sufficient capital if or when needed.
• Dependence on key personnel.
• Impact of recent accounting pronouncements.

Future Outlook

Management anticipates that current cash on hand and cash flows from operations will be sufficient to meet requirements for at least the next twelve months. However, continued execution of the longer-term strategic plan may necessitate drawing on the existing credit facility, securing additional debt, raising capital through equity issuance, or a combination of these methods. Future capital requirements are subject to various factors including sales growth rate, timing and extent of strategic initiative spending (e.g., R&D, international expansion), new product introductions, market acceptance of solutions, and overall economic conditions, including inflation and global supply imbalances. Tariff-related charges are projected to have an annualized gross margin impact of less than 100 basis points.

Management Comments

• Ended the second quarter of 2025 with $10.2 million in net revenues, a 20.9% increase compared to $8.4 million in the same period last year.
• Revenues were driven by growth in our core domestic and international business of 15.3% and 33.9%, respectively, as well as with an increase of 42.1% in our pharma services and clinical trials business.
• Gross profit for the second quarter of 2025 was $6.5 million, an 18.2% increase compared to $5.5 million in the same period last year, primarily driven by additional revenue from volume growth in our core domestic and international businesses.
• Gross margin was 63.5% for the three months ended June 30, 2025, a decrease from 65.0% in the prior year period due to a one-time inventory valuation adjustment in the prior year.
• Operating expenses for the second quarter of 2025 were $6.8 million, compared to $6.7 million for the same period last year, driven by an increase in selling, general, and administrative expenses, and research and development expenses.
• At this time, we expect tariff-related charges to have a gross margin impact of less than 100 bps on an annualized basis.
• Domestic core revenues were $7.1 million, an increase of 15.3% over the prior year period, primarily due to higher consumable volumes, driven by new patient starts and market share gains from new and existing accounts, supported by a strong underlying SCIg market.
• International core revenues were $2.2 million, an increase of 33.9% over the prior year period, primarily due to higher consumable and pump volumes, driven by prefill patient conversions, new patient starts, and market share gains within existing markets, and entry into new geographic markets.
• Pharma services and clinical trials net revenues were $0.9 million, an increase of 42.1% over the prior year period, primarily driven by higher revenues from product sales for clinical trials.
• The decrease in gross margin was primarily driven by a favorable inventory valuation adjustment that occurred in the prior year period and tariff related charges in the current year, partially offset by volume efficiencies, and stronger margins in our pharma services and clinical trial business due to revenue mix.
• The increase in selling, general and administrative expenses was primarily driven by increases in recruiting expenses related to the Chief Commercial Officer search, partially offset by lower compensation-related expenses related to timing of hiring that role.
• Research and development expenses increased $0.06 million, or 5.3%, to $1.2 million during the three months ended June 30, 2025, as compared to $1.1 million in the prior year period, primarily due to higher temporary headcount spend related to our new product development.
• Our net loss decreased to $0.2 million in the three months ended June 30, 2025, as compared to the prior year period, primarily driven by an increase in gross profit of $1.0 million due to increased revenues, partially offset by an operating expense increase of $0.1 million.
• The increase in the first half of 2025 was driven by an increase in net revenues of $3.2 million.
• The decrease in gross margin was primarily driven by a favorable inventory valuation adjustment that occurred in the prior year period and tariff related charges in the current year, partially offset by volume efficiencies.
• Selling, general and administrative expenses increased $0.7 million, or 6.2%, during the six months ended June 30, 2025, as compared with the prior year period, primarily due to increases in compensation and benefits expense, legal, and audit fees.
• Research and development expenses decreased $0.3 million, or 11.5% during the six months ended June 30, 2025, as compared with the same prior year period, primarily due to lower project spend for outsourced activities.
• Our net loss decreased $1.6 million in the six months ended June 30, 2025, as compared with the same prior year period, mostly driven by an increase in gross profit of $1.9 million or 18.3%, partially offset by an increase in operating expenses of $0.3 million or 2.5%.
• We expect that our cash on hand and cash flows from operations will be sufficient to meet our requirements at least through the next twelve months.
• Continued execution on our longer-term strategic plan may require the Company to draw on our credit facility, take on additional debt, raise capital through issuance of equity, or utilize a combination of the above.

Industry Context

KORU Medical Systems operates within the specialized subcutaneous drug delivery market, focusing on solutions for conditions like Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The reported growth in domestic core revenues is supported by a 'strong underlying SCIg market,' indicating favorable industry trends for subcutaneous immunoglobulin therapies. The company's expansion into new international markets and increased revenues from pharma services and clinical trials suggest its active participation in the broader biopharmaceutical drug development landscape, positioning its FREEDOM™ System as a key delivery platform for new drugs. The mention of competitive products as a risk highlights the dynamic nature of the medical device and drug delivery industry.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not presently a party to any litigation or other legal proceedings that is believed to be material to its financial condition.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and significant reduction in net loss, indicating improving financial health. Potential future capital raise could lead to dilution but also fund growth initiatives.
• Employees: New Chief Commercial Officer appointment and ongoing stock-based compensation plans provide incentives and career opportunities.
• Customers: Increased consumable volumes and new patient starts suggest strong product adoption and satisfaction.
• Creditors: Extension of credit facility terms indicates continued lender confidence and provides financial stability.
• Suppliers: Mention of raw material availability and costs as a risk factor indicates potential supply chain considerations.

Next Steps

• Continue investing in research and development to develop new products.
• Continue investing in manufacturing equipment to support future growth and operating efficiencies.
• Execute on the longer-term strategic plan, potentially utilizing credit facilities, additional debt, or equity financing if needed.
• Monitor and manage tariff-related charges to minimize gross margin impact.

Key Dates

Recommendation

The company demonstrated robust revenue growth across all segments and a substantial reduction in net loss, signaling a positive operational inflection point. Strategic management additions, such as the new Chief Commercial Officer, and extended credit facilities enhance future growth prospects and financial stability. While gross margin saw a slight decline and cash burn from operations increased, these are outweighed by the strong top-line performance and significant progress towards profitability, making it an attractive opportunity for growth-oriented investors.

Keywords

Medical Devices, Subcutaneous Drug Delivery, Infusion Systems, Home Infusion, Biopharmaceutical, Primary Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, FREEDOM System, Syringe Drivers, Clinical Trials, Healthcare Technology, KORU Medical Systems